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Abstract
Glioblastoma Multiforme (GBM) cells are highly invasive, infiltrating into the surrounding normal brain tissue, making it
impossible to completely eradicate GBM tumors by surgery or radiation. Increasing evidence also shows that these
migratory cells are highly resistant to cytotoxic reagents, but decreasing their migratory capability can re-sensitize them to
chemotherapy. These evidences suggest that the migratory cell population may serve as a better therapeutic target for
more effective treatment of GBM. In order to understand the regulatory mechanism underlying the motile phenotype, we
carried out a genome-wide RNAi screen for genes inhibiting the migration of GBM cells. The screening identified a total of
twenty-five primary hits; seven of them were confirmed by secondary screening. Further study showed that three of the
genes, FLNA, KHSRP and HCFC1, also functioned in vivo, and knocking them down caused multifocal tumor in a mouse
model. Interestingly, two genes, KHSRP and HCFC1, were also found to be correlated with the clinical outcome of GBM
patients. These two genes have not been previously associated with cell migration.
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Introduction
Glioblastoma multiforme (GBM) is the most common form of
primary brain tumor in adults [1,2]. Despite years of effort, the life
expectancy for GBM patients has not improved significantly, with
an average of about only 15 months [3]. In the US, approximately
15,000 patients die from GBM every year. The poor prognosis
partly originates from GMB’s invasive phenotype, which gives the
tumor cells the ability to infiltrate into adjacent normal brain
tissue. In pathology, a penumbra of invasive single cells can often
be detected several centimeters from the core lesion. This has
made it extremely difficult to completely eradicate a tumor by
traditional treatment modalities such as surgical resection or
radiation [4,5]. As a result tumors frequently recur and none of the
current treatment options are ultimately effective [6]. Also notably,
although the invasiveness does not necessarily correlate with the
grade of malignancy for gliomas [7], it has been shown that
invasive GBM cells may have heightened resistance to the
induction of apoptosis [8]. Therefore, chemotherapy is often
ineffective on these cells, further contributing to GBM’s poor
prognosis. Interestingly, decreasing the migratory capabilities of
tumor cells can restore a certain level of sensitivity to cytotoxic
reagents and increase the susceptibility to chemotherapeutic
treatments [9,10]. These results suggest that the invasive cell
population may represent a more effective treatment target for
GBM.
Tumor invasion is the result of a complex interaction of cancer
cells with the surrounding structures. It begins with individual cell
migration, a process that is driven by the cytoskeleton rearrange-
ment and the focal adhesion assembly [11,12]. Cell migration is
involved in many normal physiological processes, such as
embryonic development, wound healing, and inflammatory
response [13,14,15]. It is believed to be a rigidly controlled
process that is under the regulation of complex mechanisms
mediated by numerous genes. Cells of origin of GBM, be it
astrocytes or stem/progenitor cells, are intrinsically migratory.
However, the migratory capability of tumor cells varies among
patients. It is possible that the enhanced motile phenotype of GBM
cells is caused by the lost of one or more regulatory controls, as a
direct or indirect result of the numerous somatic mutations that
are frequently observed in GBM [16]. Although much has been
learned about the phenotypic profile of cell migration in GBM,
little is known about its causing mechanism. Characterizing the
molecular mechanisms may not only provide better diagnostic and
prognostic biomarkers, but also discover novel molecular thera-
peutic targets.
To shed light on the mechanism that drives GBM tumor
invasion and to identify novel molecular targets that can possibly
be used for disease management, we sought to systematically
characterize the genes inhibiting the migration of GBM cells. To
this end we adopted a pooled genome-wide RNA interference
(RNAi) screening approach [17]. RNAi knocks down the RNA
target in a sequence-specific manner and greatly facilitates the
study of individual genes [18,19,20]. Paired with genomic
sequence data, high-throughput RNAi screening is now possible,
allowing systematic functional analysis on a genome-wide scale
[21,22,23]. Using this unbiased approach, we successfully identi-
fied a number of genes that were later confirmed to regulate GBM
cell migration both in vitro and in vivo. Further investigation showed
that two of these genes are also associated with the clinical
outcome of GBM patients.
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e61915
Methods
Ethics statement
Brain tumor surgical specimens were obtained following the
protocol approved by Methodist Hospital Institutional Review
Board (IRB0907-0187). Tissue samples were obtained by The
Methodist Hospital Tissue Bank from patients with signed consent
forms, the samples were provided to us by the tissue bank without
any of the patient’s identity information. All animal experiments
were performed following the protocol approved by The
Methodist Hospital Institutional Animal Care and Use Committee
(AUP-0811-0037). All surgery was performed under Ketamine/
Xylazine cocktail anesthesia, and all efforts were made to
minimize suffering.
Cell lines and primary cells
All the cell lines were purchased from the American Type
Culture Collection (ATCC) and grown in DMEM with 10% fetal
bovine serum (FBS) and penicillin/streptomycin at 37uC in a
humidified incubator with 5% CO2. They were used within 10
passages, for less than 6 months after receipt. Cell lines were
characterized by ATCC by morphology check, growth curve
analysis, and short tandem repeat DNA profiling. After receipt,
cells were confirmed to be free from mycoplasma contamination
using a mycoplasma detection kit (Roche Applied Science).
Brain tumor surgical specimen were obtained following the
protocol approved by our Institutional Review Board. Briefly,
fresh tumor samples obtained within 2 hours of surgical resection
were rinsed with PBS, mechanically minced with scissors, and
digested for 30 minutes at 37uC with trypsin. Cells were
extensively triturated and filtered through a 40 mm filter to collect
single cells. They were then cultured in suspension at 105 cells/ml
in serum free medium containing bFGF, EGF, and heparin.
Neurospheres formed within a week and the single cells were
removed using cell strainers. The cells were maintained in the
neurosphere form and used for migration assay within 2 weeks.
Before the assay the neurospheres were dissociated with accutase
to single cells.
Lentivirus transduction
The Decode RNAi viral screening kit was purchased from
Open Biosystems. Virus was provide as high-titer pre-packaged
lentiviral particles produced from a pGIPZ vector. The shRNA
sequences were designed to be microRNA-adapted to enhance the
efficiency and each construct was barcoded for identification. For
transduction, 1.56106 U87 cells were plated in a 100 mm dish.
The next day, the medium was replaced with 3 ml virus
containing medium. After 6 hours incubation, the virus was
removed and the cells were further cultured in fresh medium for
48 hours. Non-transduced cells were then removed by incubating
the cells in puromycin containing medium for 6 days. The
transduction rate was monitored by the expression of GFP. As a
negative control, mock transduced cells were prepared by
transducing with virus from the same lentiviral vector harboring
a scrambled shRNA sequence (Open biosystems Catalog#
RHS4346).
To build the overexpressing cell lines, the coding sequences of
the targeting genes were cloned into a pLentif6/V5 (Life
Technologies) vector and lentivirus was prepared following the
manufacturer’s instruction. After infection non-transduced cells
were removed by antibiotic selection.
Microarray hybridization
Cells of interest were collected and genomic DNA was extracted
using a Promega kit. A 250 base pair DNA fragment containing
the barcode sequence was PCR amplified using the primers
supplied by the vendor (Open Biosystems). The DNA was then
labeled with cyanine fluorescent dyes using Agilent’s genomic
DNA labeling kit. The labeled DNAs were then hybridized to
microarray using the Agilent oligo aCGH hybridization kit, and
the array was scanned with a Genepix scanner. The Decode RNAi
barcode microarray was supplied by the vendor (Open Biosys-
tems). It consists of 26105 K arrays spotted with sequences unique
to each shRNA. Barcode hybridizing probes have been optimized
using Agilent algorithms for assessing probe quality. Each array
contains 58,498 probe sequences (most duplicated on the array).
Cell migration assays
For Boyden chamber assay, experiments were carried out using
Matrigel invasion chambers with 8 mm pore size (BD Biosciences).
To count the migrated cells, after incubation the non-invading
cells were thoroughly removed from the upper surface of the
membrane by scrubbing. The migrated cells attached to the lower
surface of the membrane were fixed and stained with toluidine
blue. The whole membrane was then imaged using a brightfield
microscope with montage function. For microarray analysis or
further culture, cells were separately collected from the upper
chamber and lower membrane surface, trypsinized, and washed
for further treatment. For wound healing assay, 56105 cells were
seeded in 6-well plates. After 48 hours, a straight scratch was made
in each well using a pipette tip. Time-lapse images were taken and
the migrated cells were counted at different time points. All
experiments were repeated at least three times, and results were
presented as the mean with standard deviation. Student T test was
used to evaluate the statistical significance.
Cell proliferation assay
To measure the cell proliferation rate, 16104 cells were seeded
in a well of 24-well plate. Every 24 hours, cell proliferation was
measured using a MTS assay kit (Promega) for 6 days. As
confirmation viable cell count was also carried out to measure cell
proliferation. 1.56103 cells were seeded in a well of 96-well plate.
Every 24 hours cells were dissociated and viable cells free of
tryphan blue staining were counted until 6 days later. For both
experiments results are presented as the mean of 6 independent
wells with standard deviation. Student T test was used to evaluate
the statistical significance.
Cell-matrix, cell-cell adhesion assay
A Vibrant Cell Adhesion Assay kit (Life Technologies) was used
to examine the cell-matrix adhesion. Cells were stained with
calcein AM before they were plated into a Matrigel coated 96-well
plate, after 1 hour non-adherent cells were removed by careful
washing, and the adherent cells were quantified by measuring the
fluorescence intensity using a plate reader. Similarly, to measure
cell-cell interaction, calcein AM stained U87 cells were plated into
wells that were already covered with U87 cells. After 1 hour the
well was washed and fluorescence intensity was measured to
determine the number of adherent cells.
Mouse tumor model
Immunodeficient NOD/SCID mice were purchased from
Charles River and experiments were carried out in accordance
with the institutional guidelines for the use of laboratory animals.
200,000 transduced U87 cells were suspended in 10 ml sterile PBS
GBM Cell Migration RNAi Screening
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for injection. Cells were implanted subcortically into the right
hemisphere (2 mm lateral, 2 mm in front of bregma, and 2 mm
deep) using a stereotactic fixation device. After the animals died




The strategy of the multiplexed genome-wide RNAi screen is
illustrated in Figure 1. To create the starting cell population, U87
cells were transduced with the Decode RNAi human annotated
genome screening library (Open Biosystems). The library contains
3 pools of lentivirus containing a total of approximately 30,000
constructs, targeting 11,954 annotated human genes. For trans-
duction, the virus to cell ratio was controlled to obtain
approximately 100-fold coverage of each shRNA construct. To
ensure that the majority of the cells have only one copy of the
virus, a multiplicity of infection (MOI) of 0.3 was used so that only
about 10% of the transduced cells had more than one copy of the
virus. Following antibiotic selection to remove the non-transduced
cells, we obtained a mixed cell population harboring 30,000
different shRNAs.
The transduced cells were loaded into a Matrigel invasion
chamber, incubated for 12 hours, and then subjected to analysis
by two different approaches. In approach 1, the migrated and
non-migrated cells were separately collected to extract genomic
DNA. The barcode region in the shRNA constructs was PCR
amplified from the genomic DNA and labeled with either Cy3 or
Cy5 dyes. They were then hybridized to a microarray with probes
targeting the barcode sequences of the Decode library as described
in the Methods. By comparing the Cy5/Cy3 signals at each spot,
the abundance of individual shRNA in the migrated versus non-
migrated cell population can be determined. Experiments were
carried out in duplicate; the signals from all probes targeting the
same construct in the two independent microarrays were averaged
for assessing the effect of the shRNA. In approach 2, the migrated
cells were collected, amplified, and then loaded for migration
selection again. The procedure was repeated a total of 5 times until
the migrated cells were dissociated into single cells for clonal
expansion. In approach 2 the experiment was repeated once and
from each experiment, we established 150 clones. Genomic DNA
was then purified from each clone and the corresponding shRNA
sequence was determined by sequencing.
Figure 1. The multiplexed RNAi screening approaches. U87 cells were transduced with the lentivirus library. Following antibiotic selection, the
cells were used for migration assay using a Matrigel invasion chamber. In approach 1, migrated and non-migrated cells were separately collected for
genomic DNA extraction. The barcode region was amplified by PCR and labeled with CY3 or CY5, and used for microarray analysis to compare the
shRNA abundance in either population. In approach 2, the migrated cells were collected and amplified, then subjected to another round of migration
selection. The procedure was repeated 5 times before the final cells were used for single cell amplification in 96-well plates. After clonal expansion,
genomic DNA was extracted and sequenced to determine the shRNA sequences in each clone.
doi:10.1371/journal.pone.0061915.g001
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The Cy5/Cy3 values for all the probed shRNA constructs are
sort ordered and ranked in Table S1. Since the Cy5 and Cy3
signals at each spot should be proportional to the abundance of
corresponding shRNA in the migrated and the non-migrated cell
populations, this result provides an overall assessment for almost
all the shRNAs on their effects on GBM cell migration. The Cy5/
Cy3 ratio values were ranked from high to low and the ranking
percentile was used for assessing the inhibitory effect of the shRNA
on cell migration. This percentile translates to the percentage of
shRNAs that have lower Cy5/Cy3 values than it is, so that a
higher percentile represents a higher Cy5/Cy3 value. Hence, the
targeting gene is more likely to inhibit GBM cell migration. In
approach 2, a total of 300 clones were established and subjected to
direct sequencing to determine the corresponding shRNA.
Interestingly, only 29 difference constructs were identified, among
which, 25 sequences appeared at least once in both experiments.
The sequences and corresponding genes are shown in Table 1.
This result suggest that the selection pressure was successfully
applied, leading to effective enrichment of the adapted cells.
However, it needs to be noted that in this approach, the selection
pressure is not specific to the cell’s migratory capability. shRNAs
promoting cell proliferation may also be enriched as they give the
cells an advantage during the in vitro amplification step. Indeed,
not all of the 25 genes have high percentile in the results from
approach 1 (Table 1). Since approach 2 also generated pure
clones harboring the 25 shRNAs, we next used these clones for
secondary screening to validate the effects of these primary hits on
GBM cell migration.
Validation of the screening results in vitro
Two independent cell migration assays were used to measure
the migratory capability of the cell lines harboring the shRNAs we
identified through RNAi screening. In the first assay, we used a
Matrigel invasion chamber. After 8 hours of incubation, cells
migrating to the lower surface of the membrane were stained for
microscopic examination and compared to mock transduced cells
produced by lentivirus harboring a scrambled shRNA sequence to
determine the shRNA effect. Since U87 cells have strong
migratory capability, usually thousands of cells were observed on
the lower surface of the membrane. To accurately and reliably
count the migrated cells, we developed an automated microscopic
image processing program (Method S1 and Figure S1). This
tool enabled us to automatically quantify and statistically evaluate
the results (Figure 2A and B). In the second measurement, we
used a wound healing assay. A gap of approximately 250 mm was
made by scratching with a pipette tip and the number of cells
migrating across the border was monitored by time-lapse imaging.
After 8 hours, cells exhibited different levels of migration until the
gap was filled after 24 hours (Figure 2A). Overall, of the 25 cell
lines we tested, 7 of them were observed to have significantly
improved migratory capability in both assays (Figure 2A, B and
C), suggesting an inhibitory role of the corresponding genes on cell
motility. We mentioned above that some of the 25 primary hits did
Table 1. Genes identified in the RNAi screening.
Gene Target sequence Colony frequency Inhibition ranking
FIGNL1 CCAGGAAACAGATAGTAAT 68 (22.7%) 44.668.8%
SENP8 CTGGCTCAATGACCATATT 39 (13.0%) 55.7610.1%
LCTL GAAACTTGCTCTATCAACA 33 (11.0%) 51.8613.4%
VAV1 GGCAGAAATACATCTACTA 32 (10.7%) N/A
HCFC1 CAACCACCATCGGAAATAA 20 (6.7%) 86.667.5%
GOLGA6L5 AGCTAAACATCACCATCAT 16 (5.3%) N/A
B3GAT2 AAATAACTGCACTAAGGT 12 (4.0%) 87.967.3%
FLNA CCTACTTTGAGATCTTTA 12 (4.0%) N/A
KHSRP CGAGAAGATTGCTCATATA 11 (3.7%) 95.561.0%
DLK1 CACATGCTGCGGAAGAAGA 8 (2.7%) 77.569.3%
PROKR1 CCTGGTCCGCTACAAGAAA 6 (2.0%) 94.364.1%
TERF1 GTAATGATGTTGAAATGGAA 6 (2.0%) N/A
LRRIQ3 CTCACTTTAACTTACCAAA 5 (1.7%) 85.3612.8%
TWF1 CAACTTGTGATTGGATCAT 4 (1.3%) 82.968.0%
NOB1 CTCCTGTGCATTTAATTAA 3 (1.0%) 90.368.8%
ERCC2 CTCACCGACTGCTTCCTGA 3 (1.0%) N/A
RIPK1 ACCAACAGATGAATCTATA 2 (0.7%) 15.8615.9%
HEPHL1 CCCAACAGGATAGGCAGTA 2 (0.7%) 41.1614.7%
SMAD1 CTATTTCATCTGTATCTT 2 (0.7%) 85.3611.1%
XPO4 CAGCGATTCTTAAGAGTGA 2 (0.7%) 52.9617.3%
BUB1 CAGGAAAGGTCCGAGGTTA 2 (0.7%) 27.367.9%
AMMECR1 CTCCTTCCTTCCACATTTA 2 (0.7%) 80.966.5%
VPS18 CATTGTACGTGCTAAATGA 2 (0.7%) 33.6611.4%
DUSP12 GTCGAAGTGTGGCCATAAT 2 (0.7%) 88.265.7%
CCNC CTCCTTTCATGATAGCTTT 2 (0.7%) 68.5610.0%
doi:10.1371/journal.pone.0061915.t001
GBM Cell Migration RNAi Screening
PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e61915
not rank high by approach 1; however, except for FLNA which
has no corresponding probe on the array, the ranking percentiles
of all the other 6 shRNAs confirmed by the two migratory assays
are higher than 80% (Table 1), further supporting an inhibitory
role specifically on cell migration. To further confirm this result,
we also carried out experiments to directly exclude the effect of the
shRNAs on cell proliferation. The proliferation of cell lines
harboring the 7 shRNAs were monitored daily for 6 days and
compared with mock-transduced cells. None of the gene
knockdowns caused a significant cell proliferation change in U87
cells using either MTS assay or viable cell count measurement
(Figure S2). In order to confirm the knockdown effects of the
shRNAs on protein level, western blotting was carried out
comparing the mock-transduced cells and the shRNA transduced
cells. The results confirmed that the 7 shRNAs induced
downregulation of the corresponding protein (Figure 2D). In
summary, our screening identified 7 genes whose corresponding
proteins may participate in the inhibition of GBM cell migration in
vitro.
Validation of the screening results in vivo
We further tested whether the 7 genes function in vivo to regulate
GBM cell migration. U87 cells harboring the shRNAs were
amplified for brain injection into immunodeficient mice. A total of
10 mice were injected for each cell line. All injections led to
aggressive tumor growth in the animal brain and the animals died
after approximately 1 month. No significant difference in the
survival length was observed among all the cell lines tested (data
not shown). After animal death, the brains were dissected for
pathological examination. Standard H/E staining revealed tumor
growth at the site where cells were injected, with a clear margin
that differentiated them from the normal brain tissue (Figure 3).
For mock transduced cells, although the resulting tumors varied in
size significantly, they were all unifocal even that some tumors
have invaded into the other hemisphere. Different pathology was
observed for 3 of the 7 cell lines tested: those with shRNAs
targeting genes HCFC1, KHSRP and FLNA; while the tumors for
the other 4 cell lines are indistinguishable from the control tumors.
For these three cell lines with shRNAs targeting HCFC1, KHSRP
and FLNA, multifocal tumors were detected in some of the
animals (Figure 3). The frequency of multifocal tumor was not
high, occurring in 3 out of 10, 2 out of 10, and 3 out of 10 animals
for HCFC1, KHSRP and FLNA cell lines, respectively. Multiple
tumors were observed clearly separated from each other. The fact
that some tumors were observed in the left hemisphere suggests
that this separation is highly unlikely to be caused by technical
reasons related to the injection procedure, rather it is a result of
cell migration and amplification from the primary tumor. The fact
that separation is not observed in any of the animals injected with
mock transduced cells indicates that it is a result of gene
downregulation, suggesting a role for genes HCFC1, KHSRP
and FLNA in GBM cell migration in vivo.
Validation of the gene effects with other GBM cells and
secondary shRNAs
The above screening and validation experiments were all
carried out on U87 GBM cell line. In order to test whether the
effects of HCFC1, KHSRP, and FLNA are general to GBM cells,
two different GBM cell lines, A172 and LN-229, were used in the
Matrigel invasion chamber experiment to further test the gene
functions. In addition, primary GBM cells were cultured from
patient surgical specimen and used for the cell migration assay.
The primary cells were maintained in the neurosphere form
(Figure S3). Before migration assay, they were dissociated into
single cells to load into the Matrigel invasion chamber. After
incubation, cells migrating to the lower surface of the membrane
were stained and counted using the automated image processing
program (Figure S1). Knockdown of the three genes led to
significant increase of cell migration in all conditions except for
HCFC1 in the A172 cell line, in which a higher average was
observed but was not statistically significant (Figure 4A). These
results support that HCFC1, FLNA, and KHSRP are inhibitory
genes for the migration of GBM cells.
To verify the gene targets and avoid off-target effect, a
secondary shRNA lentiviral construct was built and tested for
genes HCFC1, FLNA and KHSRP. The sequences of the shRNAs
were shown in Table S2. Western blot showed that these shRNAs
were effective on down-regulating the corresponding proteins
(Figure 4B), and Boyden Chamber migration experiment
confirmed that the cells gained high motility after the down-
regulation of the proteins (Figure 4C). This result verified that the
effect of the shRNAs were through the targeted proteins.
Association of the gene expression with clinical outcome
Tumor cell invasiveness directly contributes to the poor
prognosis of GBM. In order to test whether the genes identified
in this study are possibly involved in the tumor progression in
patients, we sought to identify whether there is any association of
the genes with the clinical outcome of GBM patients. For this
study we used the most recent TCGA (The Cancer Genome Atlas)
database, which contains data from 548 GBM patients. Interest-
ingly, high expression levels of HCFC1 and KHSRP were
observed for patients who survived long after surgery. Specifically,
70% of the patients who survived more than 3 years express higher
than median level of HCFC1 as detected by the two probes
targeting the gene. When the patients surviving more than 5 years
were analyzed, even higher percentages were observed, with
91.1% and 83.3% of the patients above the median level as
detected by the two probes, respectively. For KHSRP, approxi-
mately 70% of patients survived more than 3 or 5 years, as
detected by 2 of the 3 probes targeting the gene (Table 2 and
Figure S4). Statistical analysis showed that the phenomenon is
significant, supporting a possible role for HCFC1 and KHSRP in
disease progression and suggesting that they may be used as novel
prognostic markers for GBM patients.
There are evidences suggesting that decreasing the migratory
capabilities of tumor cells may sensitize them to cytotoxic reagents
[9,10]. Considering that most of the long survival patients received
chemotherapy (87% of the patients survived longer than 3 years
and 92% of the patients survived longer than 5 years), we sought to
test if the high-expression of the genes can affect the chemotherapy
efficiency. Cytotoxicity was measured every 48 hours over 6 days
for the overexpressing U87 cells treated with 20 mM of
temozolomide (TMZ). The result (Figure 5) showed that one of
the cell line which overexpresses HCFC1 had enhanced cytotox-
icity response at all the time points tested, while the other cell line
overexpressing FLNA was observed to be sensitized to TMZ after
48 hours only. This result raises the possibility that the long
survival may be not only caused by the decreasing of tumor cell
migration, but also the enhancement of the chemotherapy
efficiency, although more evidence is needed to draw the final
conclusion.
Discussion
Genome-wide RNAi screening has been increasingly used to
study diverse biological processes.[23] Particularly, pooled shRNA
screening is widely used because it has the advantages of low cost,
GBM Cell Migration RNAi Screening
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high speed, and high coverage [24,25]. This approach allowed us
to carry out an unbiased study to systematically characterize all the
human annotated genes for their affects on human GBM cell
migration. Although a limited number of clones were sequenced,
only 29 constructs were identified after sequencing 300 clones,
highly suggesting that these shRNAs affect GBM cell migration.
Also, the use of two different screening approaches and the
consistency between the results further validate the effectiveness of
our screening. Among the 7 screening hits that were confirmed by
cell migration assays, 4 proteins were previously shown to interact
with cytoskeleton or possibly be associated with cell migration. For
example, FLNA (filamin) is known to crosslink actin filaments into
orthogonal networks and participate in the anchoring of mem-
brane proteins for the actin cytoskeleton [26,27]. Interestingly, it
was recently shown that FLNA can suppress breast cancer cell
migration and invasion by regulating focal adhesion disassembly
[28]. This is highly consistent with our finding of FLNA’s
inhibitory role in GBM cell migration. Another actin interacting
protein identified is TWF1 (twinfilin-1), which binds to actin
monomer and prevents assembly of the monomer into filaments
[29,30]. Twinfilin-1 may serve as a link between rapid actin
filament depolymerization and assembly in cells, therefore
regulating GBM cell migration. However, it is unclear how the
inhibitory function is exerted. In fact, a recent RNAi screen has
identified twinfilin to promote lymphoma progression, suggesting a
role promoting cell motility [31]. Similarly, PROKR1 was
previously shown to be involved in cell motility, but it stimulates
lung cancer cell migration and promote metastasis [32,33].
Figure 2. Identification of potent migration inhibiting genes. Seven genes from the screening hits were confirmed to affect U87 cell
migration. (A) Column 1, a representative area showing the migrated cells attached to the lower membrane surface of the Matrigel invasion chamber.
Cells were either mock transduced or transduced with shRNAs targeting the indicated genes. Columns 2 to 4, images showing cell migration in a
wound healing experiment at indicated time points. Scale bar, 100 mm. (B) Quantification of the cell migration in the Matrigel invasion chamber
experiments. n = 3. *, P,0.05. (C) Quantification of the cell migration in the wound healing experiments. n = 3. *, P,0.05. (D) Confirmation of the
protein knockdown by western blotting.
doi:10.1371/journal.pone.0061915.g002
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Further study is required to determine why the opposite function
on cell migration was observed in this study. Different regulatory
networks may be involved in various tissue types. The last gene is
B3GAT2, which is involved in the synthesis of the human natural
killer-1 (HNK-1) carbohydrate epitope, a sulfated trisaccharide
involved in cellular migration and adhesion, particularly in the
nervous system [34]. Our data confirms its role in cell motility in a
tumor originating from brain.
Three genes were shown to be able to regulate GBM cell
migration in vivo in an animal tumor model. The down-regulation
of these genes significantly enhanced the migratory capability of
GBM cells but no cell morphology or cytoskeleton structure
change was detected (Figure S5A, B). Surprisingly, the cell-
matrix interactions are changed divergently by the down-
regulation of these genes – while the knocking-down of FLNA
reduced the cell-matrix adhesion, the effects of the knocking-down
of HCFC1 and KHSRP (Figure S5C) were enhancing. On the
other hand, no effect on cell-cell adhesion was observed for the
three genes (Figure S5D). These results suggest that although the
cell motility effect of these genes are likely though regulating cell-
matrix interaction, their mechanisms are different which remain to
be further investigated. Among the three genes, FLNA is known to
interact with actin as aforementioned. The other two genes,
KHSRP and HCFC1, have not previously been reported to
directly regulate cell motility. KHSRP encodes for a KH-type
splicing regulatory protein, which is a multifunctional RNA-
binding protein involved in mRNA decay and alternative pre-
mRNA splicing. It promotes the rapid decay of AU-rich element
(ARE)-containing mRNAs. Genes regulated by KHSRP were
previously thought to be involved in cell proliferation, stress
response, and cancer [35,36,37]. However, in our experiment,
KHSRP did not affect U87 proliferation; thus, the enrichment of
this gene in our screen is likely caused by other roles of the gene in
GBM cells. The last gene, HCFC1, is also a well characterized
gene encoding for host cell factor C1. It is well known to control
the cell cycle and transcriptional regulation during herpes simplex
virus infection [38]. There are indirect evidences suggesting that
the protein may be involved in cell migration. First, structure
analysis showed that the protein contains a fibronectin-like motif,
implicating a role related to cell-matrix interaction. Second,
HCFC1 is known to interact with CREB3, a protein previously
shown to be involved in leukocyte migration [39,40]._ENREF_37
This study further shows that the protein may have a role in cell
migration regulation in processes other than virus infection.
Molecules affecting GBM cell migration has attracted much
research interest, for its potential to be used as better diagnostic/
prognostic markers, or design more effective targeted therapy. It
has been shown that gene expression signatures in high-migratory
glioma cells are directly correlated with short patient survival [4].
More recently, miRNA expression has been systematically
characterized in migrating GBM cells, and miRNAs promoting
cell migration has been discovered to be enriched in poor grade
glioma [41,42]. In our study, we find two genes (KHSRP and
HCFC1) that are associated with the clinical outcome of long-
Figure 3. Multifocal brain tumor resulting from the gene knockdown. U87 cells were either mock transduced or transduced with shRNA
virus before they were injected into the mouse brain. A total of 10 animals were used for each group. Mock transduced cells caused unifocal tumors
varying in sizes (three examples were shown with small to big sizes). Knockdown of three genes resulted in multifocal tumors in some of the animals
(3 animals for HCFC1 knockdown, 2 animals for KHSRP knockdown, and 3 animals for FLNA knockdown). Tumors are indicated by yellow arrow heads.
Scale bar, 1 mm.
doi:10.1371/journal.pone.0061915.g003
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surviving GBM patients. However, although most long-surviving
patients have expression levels above the median values, high
expression of the two genes do not necessarily lead to long survival
length. This may be explained by the fact that the tumor
progression state varied when the patients underwent surgical
treatment, so that many patients may already have had extensive
tumor invasion, even though they express high levels of inhibitory
genes. The same reason may explain the fact that no significant
correlation was observed on low expression of the two genes with
short patient survival -because the survival time is counted as the
days after tumor surgical removal other than the days after tumor
initiation, the short-survival patients may actually be a mixture of
patients carried tumors for various length. Nevertheless, expres-
sion levels of the two genes can be used clinically as supplemental
indicators for patient survival prediction but not independent
prognosis markers. The therapeutic application of the genes
identified in this work needs to be further explored. In the past,
research was focused on the identification of migration promoting
genes so that potential treatment could be designed using
Figure 4. Validation of the gene effects with other GBM cells
and secondary shRNAs. (A) The effect of the shRNAs on GBM cell
lines A172, LN-229 and primary GBM tumor cells. Experiments were
carried out using Matrigel invasion chamber. *, P,0.05, n = 3. (B) Protein
expression change after the treatment of a secondary shRNA sequence
targeting genes HCFC1, FLNA and KHSRP. (C) The effect of the
secondary shRNAs on U87 cell migration. Experiments were carried out
using Matrigel invasion chamber. *, P,0.05, n = 3.
doi:10.1371/journal.pone.0061915.g004
Table 2. Correlation of patient survival length with HCFC1
and KHSRP expression.
HCFC1 HCFC1 KHSRP KHSRP KHSRP
probe 1 probe 2 probe 1 probe 2 probe 3




70.0%* 70.0%* 70.0%* 70.0%* 50.0%
(30 patients) (p = 0.004) (p = 0.002) (p = 0.003) (p = 0.013)
Survival .5
yrs
91. 7%* 83.3%* 66.7%* 75.0%* 58.3%
(12 patients) (p = 0.001) (p = 0.007) (p = 0.047) (p = 0.027)
Data are presented as the percentage of patients with expression above
median level.
doi:10.1371/journal.pone.0061915.t002
Figure 5. Effect of the gene overexpression on cytotoxicity
response. (A) Cells were lentivirus transduced to overexpress the
proteins of interest. (B) Cell viability after the treatment of 20 mM TMZ
over 6 days. *, p,0.05, n = 3.
doi:10.1371/journal.pone.0061915.g005
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inhibitors of the corresponding protein targets [43]. In order to
translate the migration inhibitory mechanism to therapeutic
strategy, further illustration of the complete pathways involved is
required.
Supporting Information
Figure S1 Automated cell counting program. (A) Raw
image. (B) Image after processing, cells are labeled with different
colors for clarity. (C) Magnified image of the box area in B, the
accuracy of cell detection is over 95%. Particles on the membrane
(an example pointed by red arrow) are excluded.
(TIF)
Figure S2 The effect of gene knockdown on U87 cell
proliferation. Cells were infected with shRNA lentivirus
targeting the indicated genes (or mock transduced) before
experiments. Cell proliferation was monitored every 24 hours
using two methods, MTS assay or viable cell count, for 6 days.
Results were shown as the absorbance at 490 nm (A490) in MTS
assay (left), or the number of viable cells counted (right).
Experiments were repeated 6 times and results were shown as
average with standard deviations.
(TIF)
Figure S3 Primary culture of GBM cells. (A) Fresh tumor
samples were obtained within 2 hours of surgery. (B) Neurospheres
form within 7 days in suspension culture in serum free medium
containing bFGF. (C) After removing the attached cells as well as
non-proliferating single cells, pure neurospheres were obtained.
(TIF)
Figure S4 Association of HCFC1, KHSRP, and FLNA
expression with patient survival length. Data was collected
from The Cancer Genome Atlas (TCGA) and analyzed for each
probe corresponding to the genes of interest separately. A
horizontal line was drawn at median expression level, a vertical
line was drawn at 5 years survival length. For both probes of
HCFC1, and probes 1 and 2 for KHSRP, significantly more
patients surviving more than 5 years were observed with high
expression level, as indicated by the red regions compared to the
green regions. No significant differences were observed for other
probes.
(TIF)
Figure S5 The Effect of HCFC1, KHSRP, and FLNA
knocking-down on cell morphology, cell-matrix adhe-
sion and cell-cell adhesion. (A) Phase contrast imaging shows
no detectable cell morphology change after the down-regulation of
HCFC1, KHSRP or FLNA. GFP expression shows that the
shRNA treated U87 cells were successfully transduced. (B) F-actin
structure of the U87 cells treated with shRNAs. Arrow pointed are
focal adhesion structures. (C) Cell-matrix adhesion after the
knocking-down of the three genes. *, p,0.05, n= 4. (D) Cell-cell
adhesion after the knocking-down of the three genes.
(TIF)
Table S1 Screening approach 1 result. The Cy5/Cy3 ratio
values from all the probes were ranked from high to low and the
ranking percentile was used for assessing the inhibitory effect of the
shRNA on cell migration. This percentile translates to the
percentage of shRNAs that have lower Cy5/Cy3 values than it
is, so that a higher percentile represents a higher Cy5/Cy3 value.
The targeting genes for probes with high ranking are more likely
to inhibit GBM cell migration
(XLSX)
Table S2 Target sequences of the secondary shRNAs
(DOCX)
Method S1 Image processing pipeline
(DOCX)
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